Caribou Biosciences, Inc. Cash Flow Statement
CRBU|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Caribou Biosciences, Inc. used $111M in operating cash flow and negative free cash flow of $112M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$148.1M | -$102.1M | -$99.4M | -$66.9M | -$23.4M |
| Depreciation & Amortization | $3.6M | $3.5M | $1.6M | $984.0K | $751.0K |
| Operating Cash Flow | -$111.0M | -$93.3M | -$91.0M | -$32.5M | -$32.0M |
| Capital Expenditures | $1.4M | $11.6M | $6.5M | $2.1M | $884.0K |
| Free Cash Flow | -$112.4M | -$104.9M | -$97.4M | -$34.6M | -$32.9M |
| FCF Margin | -1006.8% | -304.3% | -703.3% | -360.9% | -568.2% |